Pfizer Inc
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 12, 2026), Pfizer Inc reported 18 stock positions worth $238.8 million. Its top holding was Oric Pharmaceuticals (ORIC) at 24.1% of the portfolio, followed by Allogene Therapeutics (ALLO, 20.9%) and Arvinas (ARVN, 14.6%). Compared with Q4 2025, it opened 1 new position, sold out of 1 and reduced 5. The biggest buy was a new position in Agomab Therapeutics (AGMB) and the biggest sale Celcuity (CELC, shares −15%).
- Most Recent 13F
- Q2 2026
- Location
- New York, NY
- CIK
- 0000078003
- Portfolio Value
- $238.8M (Q1 2026)
- SEC Filing
- 0000078003-26-000064 ↗ filed May 12, 2026
Holdings Value
Holdings 18 stocks · $238.8M
| ORIC Oric Pharmaceuticals Inc. | 24.14% | 4,780,401 | $57.7M | Reduce -11.1% |
| ALLO Allogene Therapeutics Inc. | 20.85% | 22,032,040 | $49.8M | No change |
| ARVN Arvinas Inc. | 14.63% | 3,457,815 | $34.9M | No change |
| CELC Celcuity Inc. | 13.13% | 295,652 | $31.3M | Reduce -15.4% |
| ZURA Zura Bio Ltd. | 7.05% | 2,838,913 | $16.8M | Reduce -4.4% |
| WVE Wave Life Sciences Ltd. | 5.00% | 1,875,000 | $11.9M | No change |
| PYXS Pyxis Oncology Inc. | 3.86% | 7,032,770 | $9.2M | No change |
| CRBU Caribou Biosciences Inc. | 3.50% | 4,690,431 | $8.3M | No change |
| SPRO Spero Therapeutics Inc. | 2.31% | 2,362,348 | $5.5M | No change |
| BHVN Biohaven Ltd. | 1.77% | 505,645 | $4.2M | No change |
| CRDF Cardiff Oncology Inc. | 1.57% | 2,411,575 | $3.7M | No change |
| ZNTL Zentalis Pharmaceuticals Inc. | 0.84% | 953,834 | $2.0M | No change |
| NXTC Nextcure Inc. | 0.64% | 153,354 | $1.5M | Reduce -2.7% |
| AGMB Agomab Therapeutics NV | 0.34% | 75,000 | $814K | New |
| QTTB Q32 Bio Inc. | 0.31% | 101,618 | $737K | Reduce -63.4% |
| BOLT Bolt Biotherapeutics Inc. | 0.06% | 31,305 | $137K | No change |
| DNA Ginkgo Bioworks Holdings Inc. | 0.01% | 2,928 | $17K | No change |
| SENS Senseonics Holdings Inc. | 0.01% | 2,171 | $14K | No change |
Portfolio Sells Q4 2025 → Q1 2026
Portfolio Buys Q4 2025 → Q1 2026
| AGMB Agomab Therapeutics NV | New | 0.34% | +0.34 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 17 | $170.4M | ALLO, CELC, ARVN, PYXS, WVE |
| Q1 2026 | 18 | $238.8M | ORIC, ALLO, ARVN, CELC, ZURA |
| Q4 2025 | 18 | $236.5M | ORIC, ARVN, CELC, WVE, ALLO |
| Q3 2025 | 21 | $437.5M | BNTX, ORIC, TRML, ARVN, ALLO |
| Q2 2025 | 21 | $576.2M | BNTX, ORIC, ARVN, ALLO, TRML |
| Q1 2025 | 21 | $500.8M | BNTX, ALLO, ORIC, ARVN, TRML |
| Q4 2024 | 23 | $2.6B | HLN, BNTX, ARVN, ALLO, ORIC |